IDiyas

For the Inventor, By the Inventor

Takarazuka, Japan

Masao Koshiba

USPTO Granted Patents = 15

Average Co-Inventor Count = 4.6

ph-index = 6

Forward Citations = 91(Granted Patents)


Location History:

  • Amagasaki, JA (1976)
  • Nishinomiya, JA (1977)
  • Takarazuka, JA (1976 - 1978)
  • Takarazuka, JP (1978 - 1979)
  • Nishinomiya, JP (1979 - 1983)

Company Filing History:

goldMedal15 out of 6,892 
 
Sumitomo Chemical Company, Limited
 patents

Years Active: 1976-1983

Loading Chart...
15 patents (USPTO):Explore Patents
1. 4387223 - Process for preparing 2(1H)-quinazolinone derivatives (1983-06-07),
2. 4228167 - Diuretic and vasodilating tricyclic quinazolines (1980-10-14),
3. 4202974 - Process for preparing 3,4-dihydro-2(1H)-quinazolinone derivatives (1980-05-13),
4. 4183932 - Fused quinazolinones and preparation thereof (1980-01-15),
5. 4179560 - Imidazo- and pyrimido[2,1-b]quinazolines and preparation thereof (1979-12-18),
6. 4146717 - Nitroquinazolinone compounds having antiviral properties (1979-03-27),
7. 4099002 - Quinazolinone derivatives and a process for production thereof (1978-07-04),
8. 4096144 - Process for preparing quinazolinone derivatives and their (1978-06-20),
9. 4067868 - Production of quinazolinone compounds (1978-01-10),
10. 4048168 - Process for preparing 1-polyhaloalkyl-3,4-dihydro-2-(1H)-quinazolinones (1977-09-13),
11. 4002755 - Triazoloquinazolines (1977-01-11),
12. 3980645 - Fused quinazolinones and a process for production thereof (1976-09-14),
13. 3970654 - Antiviral 2(1H)-quinazolinone derivatives (1976-07-20),
14. 3953446 - Process for preparing quinazolines (1976-04-27),
15. 3950526 - Quinazoline derivatives in pharmaceutical compositions for treating pain (1976-04-13),

Title: Masao Koshiba: Innovator in Pharmacological Chemistry

Introduction

Masao Koshiba, an esteemed inventor hailing from Takarazuka, Japan, has made significant strides in the field of pharmacological chemistry. With a remarkable portfolio of 15 patents, he continues to contribute to the advancement of medicinal chemistry through innovative processes and compounds.

Latest Patents

Masao Koshiba's latest patents showcase his expertise in synthesizing novel pharmaceutical compounds. One such patent details a method for preparing 2(1H)-quinazolinone derivatives. This innovative process allows for the production of these derivatives with excellent pharmacological activities in high yield and purity. By utilizing 3,4-dihydro-2(1H)-quinazolinone or quinazolinethione derivatives, and heating them with sulfur in an inert solvent, this method offers a significant improvement in efficiency and effectiveness in drug formulation.

Another noteworthy patent focuses on diuretic and vasodilating tricyclic quinazolines. Koshiba's work in creating novel imidazo[2,1-b]quinazolines and pyrimido-[2,1-b]quinozolines demonstrates his commitment to developing compounds with prominent pharmacological properties, particularly their diuretic and vasodilating activities.

Career Highlights

Masao Koshiba is integral to Sumitomo Chemical Company, Limited, where he has utilized his expertise to drive innovation in pharmaceutical research and development. His impact in the field is not only recognized through his patents but also through his ongoing commitment to advancing medicinal chemistry.

Collaborations

In his professional journey, Masao has collaborated with highly regarded coworkers, including Michihiro Yamamoto and Hisao Yamamoto. These partnerships emphasize the collaborative nature of scientific research and development, where collective expertise leads to groundbreaking innovations.

Conclusion

Masao Koshiba stands out as an innovative inventor in the realm of pharmacological chemistry. His 15 patents reflect his dedication to advancing medicinal compounds that can improve health outcomes. As he continues to work at Sumitomo Chemical Company, Limited, the impact of his research is sure to resonate in the pharmaceutical industry for years to come.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…